Mosaic ImmunoEngineering Inc.
CPMV evidence brief
What we can confirm
- Market Cap:
- $616K
What it means
What to watch
Prepared research question
What matters most for CPMV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CPMV
Mosaic ImmunoEngineering Inc. is a preclinical-stage biotechnology company developing cancer immunotherapies, currently operating with minimal cash and negative shareholders' equity as of mid-2026.
Key risk: Insufficient cash runway
Market Cap
$616K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Mosaic ImmunoEngineering Inc. is a preclinical-stage biotechnology company developing cancer immunotherapies, currently operating with minimal cash and negative shareholders' equity as of mid-2026.
- Cash and equivalents were $0.0M as of 2026-06-30 [sec].
- Net income was -$0.2M as of 2026-06-30 [sec].
- Shareholders' equity was -$7.8M as of 2026-06-30 [sec].
- The company has been unable to raise sufficient capital to advance any product candidate from preclinical development into clinical development [sec_mda · as of 2025-04-15].
- The company's lead program, MIE-101, is in preclinical development and an IND application is planned 18-24 months after sufficient funding is raised [sec_mda · as of 2023-03-02].
What works
- The company has assembled a management team and scientific/business advisors with recognized expertise in immunotherapy and industry/regulatory experience [sec_mda · as of 2023-03-02].
- The company has a lead program, MIE-101, with a defined preclinical plan and target indications including breast cancer, melanoma, and head and neck squamous cell carcinoma [sec_mda · as of 2023-03-02].
What to weigh
- Cash and equivalents were $0.0M as of 2026-06-30, and shareholders' equity was -$7.8M, indicating a severely constrained financial position [sec].
- The company has been unable to raise sufficient capital to advance any product candidate from preclinical development into clinical development [sec_mda · as of 2025-04-15].
- The company's existing cash resources are not sufficient to meet its liabilities and anticipated needs over the next twelve months, and it may be forced to cease operations if unable to secure additional funding [sec_mda · as of 2025-04-15].
- The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future and may never achieve profitability [sec_mda · as of 2026-04-15].
From the filings
Quoted directly from source documents.
Inability to advance product candidates
“we have been unable to raise sufficient capital to advance any product candidate from preclinical development into clinical development”
SEC MD&A · April 15, 2025
Risk of ceasing operations
“If we are unable to raise additional capital, we may be forced to cease our operations altogether.”
SEC MD&A · April 15, 2026
Risks & what to watch (4)›
Key risks
- Insufficient cash runway — Cash and equivalents were $0.0M as of 2026-06-30, with negative equity of -$7.8M [sec].
- No clinical-stage assets — Company has been unable to advance any product candidate from preclinical to clinical development [sec_mda · as of 2025-04-15].
- Going concern uncertainty — Financial statements are prepared on a going concern basis but the company may be required to cease operations if unable to secure funding [sec_mda · as of 2024-04-15].
- Dependence on capital raising — All development plans are contingent on raising sufficient capital, which may not be available on favorable terms or at all [sec_mda · as of 2026-04-15].
What to watch
- Ability to raise additional capital to continue operations and fund preclinical/clinical development [sec_mda · as of 2025-04-15].
- Progress of the lead program MIE-101 toward an IND application, which is planned 18-24 months after sufficient funding is raised [sec_mda · as of 2023-03-02].
- Outcome of the binding term sheet with Oncotelic Therapeutics, Inc. to acquire rights to certain technologies [sec_mda · as of 2026-04-15].
- Any changes in cash position, net income, or shareholders' equity in future financial reports [sec].
Sources: SEC MD&A · Generated September 27, 2026 · How we verify sources →
Run Mosaic ImmunoEngineering Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mosaic ImmunoEngineering Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Sep 2025Institutional holders
1
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| west oak capital, llc | 1 | $0 |
Frequently asked questions
What is the AI investment thesis for Mosaic ImmunoEngineering Inc.?
Mosaic ImmunoEngineering Inc. is a preclinical-stage biotechnology company developing cancer immunotherapies, currently operating with minimal cash and negative shareholders' equity as of mid-2026.
Who is the CEO of Mosaic ImmunoEngineering Inc.?
Mr. Steven W. King is the chief executive officer of Mosaic ImmunoEngineering Inc. (CPMV).
Where is Mosaic ImmunoEngineering Inc. headquartered?
Mosaic ImmunoEngineering Inc. (CPMV) is headquartered in Huntington Beach, CA, United States.
What therapeutic areas does Mosaic ImmunoEngineering Inc. focus on?
Mosaic ImmunoEngineering Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.